This is a phase 1, open-label study to assess the efficacy, safety and pharmacokinetics of
ThisCART19A (Allogeneic Anti CD19 CAR-T) bridging to HSCT in patients with refractory or
relapsed B cell acute lymphoblastic leukemia (r/r B-ALL).
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University